Bora Pharmaceuticals Co., LTD. (TPE:6472)

TPE:6472 Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	20,510	19,246	14,200	10,494	4,900	1,800
Revenue Growth (YoY)	27.43%	35.53%	35.31%	114.18%	172.28%	17.68%
Cost of Revenue	12,568	11,536	7,209	7,582	3,228	1,096
Gross Profit	7,942	7,710	6,991	2,913	1,672	703.88
Selling, General & Admin	4,075	3,633	1,444	861.52	584.52	441.16
Research & Development	761.47	694.49	298.16	129.08	41.27	36.65
Operating Expenses	4,837	4,328	1,742	990.6	625.79	477.81
Operating Income	3,104	3,383	5,249	1,922	1,046	226.08
Interest Expense	-484.23	-479.72	-171.24	-108.73	-53.62	-21.97
Interest & Investment Income	17.5	91.42	62.95	11.36	0.22	0.96
Earnings From Equity Investments	-305.9	-0.04	-	-	-	-
Currency Exchange Gain (Loss)	102.51	163.52	-67.51	47.92	-14.41	-11.91
Other Non Operating Income (Expenses)	2,358	64.53	39.98	17.41	48.02	14.28
EBT Excluding Unusual Items	4,792	3,222	5,113	1,890	1,026	207.43
Gain (Loss) on Sale of Investments	5.79	11.56	-1,044	-47.79	-	0.11
Gain (Loss) on Sale of Assets	-27.84	-27.99	-5	-2.36	-2.24	-0
Other Unusual Items	345.83	1,749	-	-	-	387.86
Pretax Income	5,116	4,955	4,064	1,840	1,024	595.4
Income Tax Expense	561.97	914.58	992.23	438.48	274.23	16.97
Earnings From Continuing Operations	4,554	4,040	3,072	1,402	749.74	578.43
Minority Interest in Earnings	-56.02	-101.39	-41.78	-9.61	-	-
Net Income	3,341	3,939	3,030	1,392	749.74	578.43
Net Income to Common	3,341	3,939	3,030	1,392	749.74	578.43
Net Income Growth	-12.41%	29.99%	117.70%	85.65%	29.62%	89.63%
Shares Outstanding (Basic)	124	122	120	117	116	115
Shares Outstanding (Diluted)	137	134	124	118	117	116
Shares Change (YoY)	7.96%	8.17%	4.93%	1.41%	0.86%	7.55%
EPS (Basic)	26.94	32.25	25.17	11.89	6.44	5.03
EPS (Diluted)	24.74	29.86	24.50	11.78	6.42	5.00
EPS Growth	-18.58%	21.90%	107.94%	83.40%	28.53%	76.28%
Free Cash Flow	2,098	452.71	4,316	1,815	1,073	28.56
Free Cash Flow Per Share	15.34	3.37	34.74	15.33	9.19	0.25
Dividend Per Share	11.669	11.669	10.002	5.133	2.041	0.936
Dividend Growth	16.67%	16.67%	94.84%	151.53%	118.14%	30.00%
Gross Margin	38.72%	40.06%	49.23%	27.76%	34.12%	39.11%
Operating Margin	15.14%	17.58%	36.97%	18.32%	21.35%	12.56%
Profit Margin	16.29%	20.47%	21.34%	13.26%	15.30%	32.14%
Free Cash Flow Margin	10.23%	2.35%	30.39%	17.30%	21.90%	1.59%
EBITDA	4,205	4,240	5,734	2,169	1,211	354.25
EBITDA Margin	20.50%	22.03%	40.38%	20.67%	24.72%	19.68%
D&A For EBITDA	1,100	857.49	485.11	246.69	165.27	128.17
EBIT	3,104	3,383	5,249	1,922	1,046	226.08
EBIT Margin	15.14%	17.58%	36.97%	18.32%	21.35%	12.56%
Effective Tax Rate	10.98%	18.46%	24.41%	23.83%	26.78%	2.85%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.